What are the indications, procedure steps, and management recommendations for colposcopy in women with abnormal cervical screening results, including both non‑pregnant and pregnant patients?

Colposcopy: Indications, Procedure, and Management

Colposcopy is indicated for women with abnormal cervical screening results that exceed specific risk thresholds, with management tailored by age, cytologic grade, and pregnancy status to prevent cervical cancer while minimizing overtreatment.

Indications for Colposcopy

Non-Pregnant Women

ASC-US (Atypical Squamous Cells of Undetermined Significance):

• Women ≥25 years with ASC-US and positive high-risk HPV require colposcopy 1, 2
• For women aged 21-24 years, repeat cytology is preferred over immediate colposcopy; colposcopy is reserved only for HSIL or greater at 12-month follow-up 1, 2
• Reflex HPV testing is the preferred triage method when liquid-based cytology is used 2

LSIL (Low-Grade Squamous Intraepithelial Lesion):

• Women aged 25-65 years with LSIL should undergo colposcopy, particularly if HPV-positive 1, 3
• The combination of LSIL and positive high-risk HPV carries a 16-19% immediate risk of CIN 2+, exceeding the 8-10% referral threshold 3
• Adolescents (21-24 years) with LSIL should have annual cytology rather than immediate colposcopy 2

ASC-H and HSIL:

• Immediate colposcopy is mandatory for all women with ASC-H or HSIL, regardless of age 2
• HSIL carries a 53-66% risk of CIN 2+ at initial colposcopy and approximately 2% risk of invasive cancer 2
• Immediate loop electrosurgical excision is an acceptable alternative to colposcopy for HSIL in adult women, except in special populations 2

Unsatisfactory Cytology:

• Repeat cytology is recommended, but colposcopy is an acceptable option for women ≥30 years 1

Pregnant Women

Conservative approach is paramount:

• Colposcopy is preferred for pregnant women with LSIL, but deferring until ≥6 weeks postpartum is acceptable 1, 2
• Colposcopy is mandatory for pregnant women with HSIL to exclude invasive cancer 2
• The primary goal during pregnancy is to exclude invasive cancer, not to diagnose or treat preinvasive lesions 2, 4
• Endocervical curettage is absolutely contraindicated in pregnancy 2
• Cervical biopsy should be avoided unless high-grade neoplasia or invasive cancer is suspected 1

Colposcopy Procedure

Technique

Visualization and Preparation:

• The cervix is examined through a colposcope with 10-16× magnification 1
• Apply 3-5% acetic acid solution to the cervix before viewing 1
• The acetic acid induces coloration changes and allows observation of blood vessel patterns 1

Assessment Requirements:

• Document whether the entire squamocolumnar junction (transformation zone) is visualized 1, 5
• If the entire transformation zone is seen, the examination is considered adequate and endocervical curettage is not required 1
• Endocervical assessment is preferred when no lesions are identified or when colposcopy is unsatisfactory 2

Biopsy Protocol:

• Perform colposcopically directed biopsies from acetowhite lesions or areas with abnormal vascular patterns 1
• The purpose is to rule out invasive disease and determine the extent of preinvasive disease 1
• Multiple biopsies may be necessary to adequately sample suspicious areas 5, 6

Special Considerations in Pregnancy

Physiologic changes complicate examination:

• Increased cervical mucus production may obscure visualization 4
• Cervical hyperemia, gland prominence, and columnar epithelium eversion are common 4
• Dysplasia may appear more prominent in pregnant patients 4
• Colposcopy should be performed by examiners experienced in pregnancy-related cervical changes 2, 4

Management Based on Colposcopy Findings

CIN 1 (Cervical Intraepithelial Neoplasia Grade 1)

Conservative management is standard:

• CIN 1 should not be treated in any age group unless persistent for ≥2 years 1, 3
• Follow-up options include HPV testing at 12 months (preferred) or repeat cytology at 6 and 12 months 2, 3
• Return to colposcopy if HPV remains positive or cytology shows ASC-US or greater 2, 3
• Treatment of CIN 1 is not recommended for pregnant women 1

CIN 2

Age-stratified approach:

• For women aged 21-24 years, observation is recommended rather than immediate treatment 1
• For women >25 years, treatment is generally recommended 3
• Acceptable treatment modalities include LEEP, cold-knife conization, laser ablation, or cryotherapy 1, 3

CIN 3

Immediate treatment required:

• Women aged 21-24 years with CIN 3 should be treated with a diagnostic excisional procedure 1
• Hysterectomy is not the primary treatment for CIN 3 1, 3
• Observation is not acceptable for CIN 3 1

Negative Colposcopy (No CIN Identified)

Risk-based follow-up:

• For women with ASC-US who are HPV-positive but have no CIN identified: HPV testing at 12 months or repeat cytology at 6 and 12 months 2
• For women with LSIL and positive HPV: repeat cotesting (cytology + HPV) at 12 months 3
• If both tests are negative, return to routine screening; if either is abnormal, repeat colposcopy 3

HSIL Without CIN 2,3 Identified

Extended surveillance required:

• Observation for up to 24 months using colposcopy and cytology at 6-month intervals is preferred, provided the colposcopic examination is satisfactory and endocervical sampling is negative 2
• If HSIL persists for 24 months without identification of CIN 2,3, a diagnostic excisional procedure is recommended 2
• If a high-grade colposcopic lesion is identified or HSIL cytology persists for 1 year, biopsy is recommended 2

Postpartum Management in Pregnancy

Defer treatment until after delivery:

• In pregnant women with LSIL who do not have CIN 2,3 or cancer at initial colposcopy, postpartum follow-up is recommended 1
• Additional colposcopic and cytologic examinations during pregnancy are unacceptable for these women 2
• Re-evaluation with cytology and colposcopy is recommended no sooner than 6 weeks postpartum for pregnant women with HSIL in whom CIN 2,3 is not diagnosed 2

Critical Pitfalls to Avoid

Age-specific errors:

• Do not defer colposcopy in favor of repeat cytology alone for women aged 30-65 years with LSIL and positive HPV; this conservative approach is reserved for women aged 21-24 years 1, 3
• Do not use immediate colposcopy for adolescents (21-24 years) with ASC-US or LSIL; annual cytology is preferred 2

Overtreatment risks:

• Do not treat CIN 1 immediately; approximately 40% of CIN 2 lesions regress spontaneously over 6 months, and overtreatment increases risk of preterm delivery by 70% 1, 7, 3
• Do not employ "see-and-treat" strategies for LSIL, even when HPV-positive; this approach is reserved for HSIL in adult women 3
• Routine use of diagnostic excisional procedures is unacceptable for women with ASC-US in the absence of histologically diagnosed CIN 2,3 2

Pregnancy-specific contraindications:

• Never perform endocervical curettage in pregnant women 2
• Do not perform cervical biopsy in pregnancy unless high-grade neoplasia or invasive cancer is suspected 1, 2
• The only indication for therapy of cervical neoplasia in pregnant women is invasive cancer 2

Testing errors:

• Do not perform HPV testing at intervals less than 12 months 2
• Do not use HPV testing to triage adolescents with ASC-US or LSIL; if inadvertently performed, results should not influence management 2
• Do not alter screening or management based on HPV vaccination status; vaccinated and unvaccinated women follow identical protocols 1

Documentation failures:

• Always document squamocolumnar junction visibility, presence of acetowhitening, presence of lesions, and colposcopic impression as minimum reporting criteria 5